Piper Jaffray Initiates Coverage on Celgene (CELG) with an Overweight; High Growth Prospects for Revlimid
Tweet Send to a Friend
Piper Jaffray initiates coverage on Celgene (Nasdaq: CELG) with an Overweight rating. Price target $77.
Piper analyst says, "The high ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says, "The high ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
